NASDAQ:CLGN - CollPlant Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.01
▼ -0.87 (-8.81%)

This chart shows the closing price for CLGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CollPlant Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLGN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for CollPlant Biotechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $9.01.

This chart shows the closing price for CLGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in CollPlant Biotechnologies. This rating has held steady since January 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2021HC WainwrightBoost Price TargetBuy$13.00 ➝ $26.00Low
12/2/2020HC WainwrightReiterated RatingBuy$13.00High
5/28/2020HC WainwrightReiterated RatingBuy$11.00 ➝ $13.00High
4/3/2020HC WainwrightBoost Price TargetBuy$7.00 ➝ $11.00Low
12/3/2019HC WainwrightReiterated RatingBuy$7.00Low
9/27/2019HC WainwrightSet Price TargetBuy$7.00Low
12/18/2018HC WainwrightInitiated CoverageBuy$7.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
CollPlant Biotechnologies logo
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $9.01
Low: $8.85
High: $10.02

50 Day Range

MA: $10.12
Low: $8.05
High: $14.25

52 Week Range

Now: $9.01
Low: $7.50
High: $23.49

Volume

29,125 shs

Average Volume

43,704 shs

Market Capitalization

$51.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CollPlant Biotechnologies?

The following equities research analysts have issued research reports on CollPlant Biotechnologies in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for CLGN.

What is the current price target for CollPlant Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for CollPlant Biotechnologies in the last year.
View the latest price targets for CLGN.

What is the current consensus analyst rating for CollPlant Biotechnologies?

CollPlant Biotechnologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CLGN.

How do I contact CollPlant Biotechnologies' investor relations team?

CollPlant Biotechnologies' physical mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company's listed phone number is 972732325600 and its investor relations email address is [email protected] The official website for CollPlant Biotechnologies is www.collplant.com. Learn More about contacing CollPlant Biotechnologies investor relations.